Zacks Investment Research on MSN
All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy
AIM ImmunoTech Inc. (AIM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. (NYSE:AIM) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback